Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
62 hedge funds and large institutions have $96.4M invested in Stemline Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 12 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 20
13% less funds holding
Funds holding: 71 → 62 (-9)
26% less capital invested
Capital invested by funds: $131M → $96.4M (-$34.5M)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $416K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$497K |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$451K |
| 3 |
RA
Royce & Associates
New York
|
+$399K |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$323K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$238K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.67M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$972K |
| 3 |
DCM
Dupont Capital Management
Wilmington,
Delaware
|
-$334K |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$303K |
| 5 |
Canada Life
Winnipeg,
Manitoba, Canada
|
-$297K |
STML Hedge Fund Activity: Q3 2015 in Review
62 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2015, worth a combined $96.4M — down 26% from $131M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of STML and 3 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 20 added.
The largest buyer was BlackRock Institutional Trust, adding an estimated $497K. The largest seller was Millennium Management, cutting an estimated $1.67M.
- 62 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2015, down from 71 in Q2 2015.
- Funds reported $96.4M of Stemline Therapeutics, Inc. stock for Q3 2015, down 26% quarter-over-quarter.
- 3 funds opened new Stemline Therapeutics, Inc. positions in Q3 2015 and 12 closed out, a net change of -9 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2015 was BlackRock Institutional Trust, an estimated $497K added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2015 was Millennium Management, an estimated $1.67M sold.
Based on aggregated 13F filings for Q3 2015.